Surrozen (SRZN) Amortizatization of Intangibles (2020 - 2026)
Surrozen (SRZN) posted quarterly Amortizatization of Intangibles of -$44000.0 for Q4 2023, up 72.84% year-over-year from -$25457.1 in Q4 2022, and up 78.85% quarter-over-quarter from -$208000.0 in Q3 2023.
Powered by 
Analysis
Surrozen (SRZN) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Surrozen's Amortizatization of Intangibles history runs 3 years deep, the most recent figure standing at -$44000.0 for Q4 2023.
- In Q4 2023, Amortizatization of Intangibles rose 72.84% year-over-year to -$44000.0; the TTM figure through Sep 2024 stood at -$44000.0 (up 94.82% YoY), while the FY2023 annual figure was -$732000.0, down 777.78% from the prior year.
- Amortizatization of Intangibles for Q4 2023 stood at -$44000.0, up from -$208000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $119000.0 in Q2 2022, with the low at -$241000.0 in Q1 2023.
- The 3-year median for Amortizatization of Intangibles is -$44000.0 (2023), against an average of -$57666.7.
- Peak annual rise in Amortizatization of Intangibles reached 72.84% in 2023, while the deepest fall reached 694.29% in 2023.
- Surrozen's Amortizatization of Intangibles stood at $105000.0 in 2021, then plunged by 254.29% to -$162000.0 in 2022, then surged by 72.84% to -$44000.0 in 2023.
- Business Quant data shows SRZN's Amortizatization of Intangibles at -$44000.0 in Q4 2023, -$208000.0 in Q3 2023, and -$239000.0 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Surrozen | 263.35 Mn | 263.35 Mn | - | 450,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 450,000.00 |
| Mar 31, 2026 | 450,000.00 |
| Dec 31, 2025 | 450,000.00 |
| Sep 30, 2025 | 450,000.00 |
| Jun 30, 2025 | 450,000.00 |
| Mar 31, 2025 | 451,000.00 |
| Dec 31, 2024 | 450,000.00 |
| Sep 30, 2024 | 358,000.00 |
| Jun 30, 2024 | 357,000.00 |
| Mar 31, 2024 | 357,000.00 |
| Dec 31, 2023 | 336,000.00 |
| Sep 30, 2023 | 324,000.00 |
| Jun 30, 2023 | 312,000.00 |
| Mar 31, 2023 | 301,000.00 |
| Dec 31, 2022 | 290,000.00 |
| Sep 30, 2022 | 279,000.00 |
| Jun 30, 2022 | 378,000.00 |
| Mar 31, 2022 | 367,000.00 |
| Dec 31, 2021 | 273,000.00 |
| Sep 30, 2021 | 330,000.00 |